BRCA in breast cancer care: tumour testing and inherited-risk testing

“They found BRCA” can describe several different findings: a change detected in the tumour, a confirmed inherited variant, or a change whose significance remains uncertain. These are not interchangeable results. One question concerns treatment selection; another may also concern future cancer risks for the patient and blood relatives. Start with the complete laboratory report and the type of sample tested.

Tumour and inherited-risk tests ask different questions

Tumour testing examines cancer-cell features that may help select treatment. Germline testing looks for changes present from birth that may run in a family; blood or saliva is commonly used. The NCI guide to biomarker testing explains that a tumour result can reveal a finding that needs separate assessment to establish whether it is inherited.

A BRCA change in the tumour therefore does not automatically prove that it came from a parent. Equally, a negative tumour test does not necessarily answer every family-risk question. Even “a blood test” does not establish its purpose: blood can be tested for inherited variants or tumour-derived DNA. The test name, its scope and the laboratory interpretation matter.

Not every variant is pathogenic

Reports may use “pathogenic”, “likely pathogenic” or “variant of uncertain significance”, often shortened to VUS. The last category means that evidence about the change is insufficient. The NCI BRCA explanation makes clear that a VUS should not be treated as a confirmed harmful variant; risk assessment continues to consider family history and other factors while its meaning remains unresolved.

Keep the exact variant notation, classification, report date and laboratory name. A message saying only “BRCA positive” removes distinctions that affect decisions. If a classification changes later, it is useful to know who will notify you and how the revised result will reach your medical record.

What a result can change in treatment

Certain harmful BRCA changes may influence drug choice in particular clinical settings. The presence of a variant does not mean the same targeted medicine is appropriate at every stage or after every previous treatment. The oncologist needs the diagnosis, stage, receptor status, treatment history and the relevant eligibility assessment.

Ask the oncologist to connect the finding to an actual decision: which option becomes relevant, what information is still needed and what the alternative would be if that option is unsuitable. Availability, indications and cost at a hospital in Turkey require confirmation by the receiving team. A genetic panel report is not itself a prescription or a guarantee that the cancer will respond.

Understanding the implications for relatives

A confirmed inherited pathogenic variant is a reason for genetic counselling. The discussion can address surveillance, possible preventive choices and testing of adult blood relatives. Carrying such a variant increases particular risks, but cannot predict with certainty whether or when an individual relative will develop cancer.

A negative result also needs context. Not carrying a known family variant differs from having a negative limited test when a substantial family history remains unexplained. Ordering the same panel for every relative without first defining the question may not be useful. For counselling, record cancer diagnoses on both sides of the family and age at diagnosis when known.

Preparing another opinion

Include the complete genetic report, sample information, tumour pathology, receptor findings and treatment history. State the immediate decision: choosing a drug-treatment phase, establishing inherited risk or discussing the risk of another cancer. These concerns are connected, but may require different specialists.

A useful oncology second opinion separates confirmed conclusions from remaining uncertainty. Preventive operations should not be decided from a forwarded line of laboratory text alone. Genetic information should lead to an understandable individual plan, rather than automatically becoming a list of procedures.